Almirall S.A. Logo

Almirall S.A.

A global biopharmaceutical company developing innovative medical solutions for skin health.

ALM | MC

Overview

Corporate Details

ISIN(s):
ES0157097017
LEI:
95980020140005007996
Country:
Spain
Address:
Ronda General Mitre 151, 08022 Barcelona
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Almirall S.A. is a global biopharmaceutical company focused on medical dermatology. Founded in 1944, the company researches, develops, manufactures, and markets medical solutions for skin health. It partners with healthcare professionals to address the needs of patients with various dermatological conditions. Almirall's mission is to apply science to provide innovative treatments that improve patients' lives. The company maintains a global presence with affiliates in Europe and the United States, and its products are available in over 100 countries.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-05-12 07:33
Notice of Dividend Amount
Información sobre el calendario del dividendo
Spanish 104.4 KB
2025-05-12 07:23
Share Issue/Capital Change
Información sobre dividendos
Spanish 188.2 KB
2025-05-12 07:15
Post-Annual General Meeting Information
Acuerdos adoptados por el Consejo de Administración
Spanish 105.9 KB
2025-05-12 07:04
Post-Annual General Meeting Information
Acuerdos adoptados por la Junta General de Accionistas 2025
Spanish 182.9 KB
2025-05-12 06:57
Investor Presentation
Almirall remite presentación sobre los resultados del primer trimestre de 2025 …
Spanish 1.3 MB
2025-05-12 06:51
Report Publication Announcement
Almirall realizará una presentación vía webcast para explicar los Resultados de…
Spanish 101.3 KB
2025-05-12 00:00
Post-Annual General Meeting Information
Acuerdos adoptados por la Junta General de Accionistas 2025
Spanish 182.9 KB
2025-04-09 11:58
Transaction in Own Shares
Operaciones del contrato de liquidez durante el primer trimestre de 2025
English 187.4 KB
2025-04-01 13:17
Pre-Annual General Meeting Information
Convocatoria de la Junta General Ordinaria de Accionistas de la Sociedad 2025 -…
Spanish 279.9 KB
2025-04-01 00:00
Pre-Annual General Meeting Information
Convocatoria de la Junta General Ordinaria de Accionistas de la Sociedad 2025 -…
Spanish 279.9 KB
2025-03-31 17:58
Pre-Annual General Meeting Information
Convocatoria de la Junta General Ordinaria de Accionistas de la Sociedad 2025
Spanish 141.0 KB
2025-03-31 00:00
Report Publication Announcement
Convocatoria de la Junta General Ordinaria de Accionistas de la Sociedad 2025
Spanish 141.0 KB
2025-03-06 07:28
Board/Management Information
Almirall anuncia el plan de transición del CFO
Spanish 72.6 KB
2025-02-24 06:43
Earnings Release
La sociedad remite presentación sobre los resultados del ejercicio 2024
Spanish 1.3 MB
2025-02-24 06:39
Remuneration Information
La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del …
Spanish 510.9 KB

Automate Your Workflow. Get a real-time feed of all Almirall S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Almirall S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.